申请人:Kondo Tatsuhiro
公开号:US20120122931A1
公开(公告)日:2012-05-17
A compound represented by the general formula (I) of the present invention, which has an EP
1
receptor antagonism:
[wherein A represents a benzene ring or the like; Y represents a C
1-6
alkylene group or the like; R
N
represents a hydrogen atom or a C
1-6
alkyl group; R
1
represents a hydrogen atom, a C
1-6
alkyl group or the like; R
2
represents a phenyl group which may have a substituent, a 5-membered aromatic heterocyclic group which may have a substituent, a 6-membered aromatic heterocyclic group which may have a substituent or the like; R
3
represents a halogen atom, a C
1-6
alkoxy group or the like; R
4
represents a hydrogen atom or the like; and R
5
represents a hydrogen atom or the like] or a pharmaceutically acceptable salt thereof is provided. Furthermore, the compound (I) of the present invention can be used as an agent for treating or preventing LUTS, in particular, various symptoms of OABs.
本发明的一种以通式(I)表示的化合物,具有EP1受体拮抗作用:[其中A代表苯环或类似物;Y代表C1-6烷基链或类似物;RN代表氢原子或C1-6烷基链;R1代表氢原子、C1-6烷基链或类似物;R2代表苯基,可能有取代基;可能有取代基的5元芳香杂环基,可能有取代基的6元芳香杂环基或类似物;R3代表卤原子、C1-6烷氧基或类似物;R4代表氢原子或类似物;R5代表氢原子或类似物]或其药学上可接受的盐。此外,本发明的化合物(I)可用作治疗或预防下尿路症状,特别是OAB的各种症状的药剂。